SARTORIUS STEDIM BIOTECH (DIM.PA) Forecast, Price Target & Analyst Ratings

EPA:DIM • FR0013154002

Current stock price

188.7 EUR
+6.5 (+3.57%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SARTORIUS STEDIM BIOTECH (DIM.PA).

Forecast Snapshot

Consensus Price Target

Price Target
€238.05
+ 26.15% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Apr 23, 2026
Period
Q1 / 2026
EPS Estimate
€1.24
Revenue Estimate
766.24M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
84.21%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
€238.05
Upside
+ 26.15%
From current price of €188.70 to mean target of €238.05, Based on 19 analyst forecasts
Low
€212.10
Median
€237.66
High
€275.10

Price Target Revisions

1 Month
-1.46%
3 Months
-3.74%

Price Target Summary

19 Wall Street analysts provided a forecast for the next 12 months for DIM.PA. The average price target is 238.05 EUR. This implies a price increase of 26.15% is expected in the next year compared to the current price of 188.7.
The average price target has been revised downward by 3.74% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

DIM Current Analyst RatingDIM Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

DIM Historical Analyst RatingsDIM Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
84.21%
DIM.PA was analyzed by 19 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about DIM.PA.
In the previous month the buy percentage consensus was at a similar level.
DIM.PA was analyzed by 19 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
Apr 23, 2026
Period
Q1 / 2026
EPS Estimate
€1.24
Revenue Estimate
766.24M
Revenue Q2Q
2.91%
EPS Q2Q
7.13%
Number of Analysts
6

Next Earnings Revisions

Revenue (1 Month)
-0.03%
Revenue (3 Months)
N/A
EPS (1 Month)
-1.01%
EPS (3 Months)
N/A

Next Earnings Summary

DIM.PA is expected to report earnings on 4/23/2026. The consensus EPS estimate for the next earnings is 1.24 EUR and the consensus revenue estimate is 766.24M EUR.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
DIM.PA revenue by date.DIM.PA revenue by date.
2.776B
-20.53%		2.78B
0.16%		2.968B
6.74%		3.219B
8.48%		3.561B
10.62%		3.939B
10.61%		4.523B
14.83%		5.111B
13.00%		5.887B
15.18%		6.535B
11.01%		7.253B
10.99%
EBITDA
YoY % growth
DIM.PA ebitda by date.DIM.PA ebitda by date.
707.9M
-44.01%		699.4M
-1.20%		857.6M
22.62%		999.17M
16.51%		1.143B
14.39%		1.301B
13.82%		1.578B
21.29%		1.823B
15.53%		2.145B
17.66%		2.38B
10.96%		2.641B
10.97%
EBIT
YoY % growth
DIM.PA ebit by date.DIM.PA ebit by date.
470.3M
-56.56%		397.7M
-15.44%		539.5M
35.66%		732.98M
35.86%		862.18M
17.63%		1.006B
16.68%		1.237B
22.96%		1.434B
15.93%		1.534B
6.97%		1.703B
11.02%		1.89B
10.98%
Operating Margin
DIM.PA operating margin by date.DIM.PA operating margin by date.
16.94%14.31%18.18%22.77%24.21%25.54%27.35%28.06%26.06%26.06%26.06%
EPS
YoY % growth
DIM.PA eps by date.DIM.PA eps by date.
4.19
-51.50%		3.50
-16.47%		4.40
25.71%		5.15
17.04%		6.16
19.58%		7.24
17.62%		9.25
27.77%		10.52
13.67%		11.61
10.32%		12.88
10.98%		14.29
10.93%

All data in EUR

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		1.24
7.13%		1.36
15.34%		1.20
28.00%		1.41
25.48%
Revenue
Q2Q % growth		766.24M
2.91%		805.77M
8.16%		780.55M
10.61%		857.12M
11.00%
EBITDA
Q2Q % growth		239.26M
9.40%		255.25M
-10.19%		245.69M
-33.42%		275.53M
-37.21%
EBIT
Q2Q % growth		188.47M
33.38%		203.02M
57.50%		186.9M
38.65%		214.58M
77.78%

All data in EUR

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

DIM.PA Yearly Revenue VS EstimatesDIM.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
DIM.PA Yearly EPS VS EstimatesDIM.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
18.07%
EPS Next 5 Year
19.04%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
9.53%
Revenue Next 5 Year
11.26%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
26.00%
EBIT Next 5 Year
22.89%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

SARTORIUS STEDIM BIOTECH / DIM.PA Forecast FAQ

Can you provide the average price target for SARTORIUS STEDIM BIOTECH stock?

19 analysts have analysed DIM.PA and the average price target is 238.05 EUR. This implies a price increase of 26.15% is expected in the next year compared to the current price of 188.7.

When does SARTORIUS STEDIM BIOTECH (DIM.PA) report earnings?

SARTORIUS STEDIM BIOTECH (DIM.PA) will report earnings on 2026-04-23.

What are the consensus estimates for SARTORIUS STEDIM BIOTECH (DIM.PA) next earnings?

The consensus EPS estimate for the next earnings of SARTORIUS STEDIM BIOTECH (DIM.PA) is 1.24 EUR and the consensus revenue estimate is 766.24M EUR.

What is the consensus rating for SARTORIUS STEDIM BIOTECH (DIM.PA) stock?

The consensus rating for SARTORIUS STEDIM BIOTECH (DIM.PA) is 84.2105 / 100 . This indicates that analysts generally have a positive outlook on the stock.